Detail akcie BB Biotech AG online

Business Summary: BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, BB BIOTECH AG revenues decreased 58% to SF530K. Net loss decreased 42% to SF206.6M. Revenues reflect Foreign exchange gains net decrease of 61% to SF490K. Lower net loss reflects Unrealized Gains/Loss decrease of 48% to SF148.8M (expense), Realized Gain/Loss decrease of 38% to SF17.8M (expense), Management fees decrease of 24% to SF27.7M (expense).